Aptevo Therapeutics Inc. (APVO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.30
- As of
Kresmion compiles this page from APVO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Aptevo Therapeutics Inc. (APVO): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-26.
See the full APVO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for APVO on one page. Preview it with sample data, then open it live with a free account.
Preview the APVO dossierActive events for APVO
- mediumEarnings above estimates
Q2-2026: Beat consensus by 13.5%, EPS $-5.31 vs $-6.1353 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 90.1% - EPS $-151.2 vs $-1527.552 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 12.2% - EPS $-6.41 vs $-5.712 estimate
- mediumEarnings above estimates
Beat consensus by 90.1% - EPS $-151.2 vs $-1527.552 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 12.7% - EPS $-33.48 vs $-38.3724 estimate
FREE, NO ACCOUNT
Every event on APVO, as it fires
You are seeing 5 of 7 events recorded on APVO since 2026-06-10.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, APVO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
APVO against its peers
APVO's return on equity of -149.4% ranks in the 70th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-03-31.
| Metric | APVO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 101551 | n/a | 8 |
| Gross margin | n/a | 80.6% | n/a | 7 |
| Operating margin | n/a | -3769.1% | n/a | 8 |
| Net margin | n/a | -4141.7% | n/a | 8 |
| Return on equity | -149.4% | -250.3% | 70 | 14 |
Peers (20): SILO, EMMA, BCAB, LSBCF.D, EOCN, MBIO, HCWB, CMND, VIVS, DCOY, SXTP, CLDI, ERNA, ABPO, CVKD, JUNS, ACUT, GRI, KALA, SLXN. Left out: VCNX (period gap), AGNPF (no annual filing), BIXT (no annual filing), GPLL (period gap), BVAXF (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (APVO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow APVO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to APVO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.